Series A · Biotech · Reykjavík, Iceland · Founded 2015 · 11–50 employees
Arctic Therapeutics is a clinical-stage Icelandic biopharmaceutical company founded in 2015 as a spin-off from the Center for Applied Genomics at the Children's Hospital of Philadelphia. The company uses bioinformatics, AI, and applied genomics to identify the genetic root causes of diseases and develop safer, more effective treatments, with lead candidates AT-001 (an oral anti-amyloid treatment for rare and common forms of dementia, including Alzheimer's) and AT-004 (targeting inflammatory skin diseases such as acne vulgaris). In January 2025, the company closed an oversubscribed €26.5M Series A round backed by the EIC Fund, Kaldbakur, Sanos Group, Cerebrum DAO, The Lurie Family Foundation, and a consortium linked to Icelandic unicorn Kerecis and Copenhagen-listed Chemometec. As of February 2026, ATx enrolled the first patients in a Phase IIa clinical trial for AT-004, and it has previously received EMA approval to initiate a Phase IIb/III trial for AT-001 in hereditary cystatin C amyloid angiopathy (HCCAA).
No open roles listed right now.